Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with or without low-dose cyclophosphamide for minimal residual autoimmunity in ANCA-associated vasculitis
NL-OMON21172Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) comparing Rituximab alone with Rituximab plus cyclophosphamide (2 arms). Started Apr 2019; status: recruiting.
02
Drugs
rituximabcyclophosphamide
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NL-OMON21172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21172.